Direct injection of functional single-domain antibodies from E. coli into human cells

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Blanco Toribio, Ana ^a   Muyldermans, Serge ^b   Frankel, Gad ^c   Fernández, Luis Ángel ^a  

^a CSIC   (Spain)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; SINGLE DOMAIN ANTIBODY; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; BETA LACTAMASE; MONOCLONAL ANTIBODY; OLIGONUCLEOTIDE; STREPTOLYSIN; STREPTOLYSIN O;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CYTOPLASM; ESCHERICHIA COLI; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; NONHUMAN; PLASMID; TYPE III SECRETION SYSTEM; CELL LINE; CHEMISTRY; CULTURE MEDIUM; GENETICS; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PROTEIN ENGINEERING; PROTEIN TERTIARY STRUCTURE; PROTEIN TRANSPORT;

BACTERIA (MICROORGANISMS);

ANTIBODIES; ANTIBODIES, MONOCLONAL; BACTERIAL PROTEINS; BASE SEQUENCE; BETA-LACTAMASES; CELL LINE; CULTURE MEDIA; ESCHERICHIA COLI; HELA CELLS; HUMANS; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; STREPTOLYSINS;

EID: 78650142695     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015227     Document Type: Article

References (77)

1. Nelson AL, Reichert JM (2009) Development trends for therapeutic antibody fragments. Nat Biotech 27: 331-337.
2. Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, et al. (2009) Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol 198: 157-174.
3. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23: 1126-1136.
4. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM (2003) Domain antibodies: proteins for therapy. Trends Biotechnol 21: 484-490.
5. Muyldermans S, Baral TN, Retamozzo VC, De Baetselier P, De Genst E, et al. (2009) Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopathol 128: 178-183.
6. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23: 1147-1157.
7. Lo AS, Zhu Q, Marasco WA (2008) Intracellular antibodies (intrabodies) and their therapeutic potential. Handb Exp Pharmacol. pp 343-373.
8. Kontermann RE (2004) Intrabodies as therapeutic agents. Methods 34: 163-170.
9. Fernández LA (2004) Prokaryotic expression of antibodies and affibodies. Curr Opin Biotechnol 15: 364-373.
10. Mazor Y, Van Blarcom T, Mabry R, Iverson BL, Georgiou G (2007) Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Nat Biotechnol 25: 563-565.
11. Critchley RJ, Jezzard S, Radford KJ, Goussard S, Lemoine NR, et al. (2004) Potential therapeutic applications of recombinant, invasive E. coli. Gene Ther 11: 1224-1233.
12. Iguchi A, Thomson NR, Ogura Y, Saunders D, Ooka T, et al. (2009) Complete Genome Sequence and Comparative Genome Analysis of Enteropathogenic Escherichia coli O127:H6 Strain E2348/69. J Bacteriol 191: 347-354.
13. Perna NT, Plunkett G, 3rd, Burland V, Mau B, Glasner JD, et al. (2001) Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. Nature 409: 529-533.
14. Croxen MA, Finlay BB (2010) Molecular mechanisms of Escherichia coli pathogenicity. Nat Rev Micro 8: 26-38.
15. Kaper JB, Nataro JP, Mobley HL (2004) Pathogenic Escherichia coli. Nature Reviews Microbiology 2: 123-139.
16. Knutton S, Lloyd DR, McNeish AS (1987) Adhesion of enteropathogenic Escherichia coli to human intestinal enterocytes and cultured human intestinal mucosa. Infect Immun 55: 69-77.
17. McDaniel TK, Jarvis KG, Donnenberg MS, Kaper JB (1995) A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. Proc Natl Acad Sci U S A 92: 1664-1668.
18. Garmendia J, Frankel G, Crepin VF (2005) Enteropathogenic and enterohemorrhagic Escherichia coli infections: translocation, translocation, translocation. Infect Immun 73: 2573-2585.
19. Cornelis GR (2006) The type III secretion injectisome. Nat Rev Microbiol 4: 811-825.
20. Galan JE, Wolf-Watz H (2006) Protein delivery into eukaryotic cells by type III secretion machines. Nature 444: 567-573.
21. Knutton S, Rosenshine I, Pallen MJ, Nisan I, Neves BC, et al. (1998) A novel EspA-associated surface organelle of enteropathogenic Escherichia coli involved in protein translocation into epithelial cells. Embo J 17: 2166-2176.
22. Munera D, Crepin VF, Marches O, Frankel G (2010) The N-terminal type III secretion signal of enteropathogenic E. coli translocator proteins. J Bacteriol 192: 3534-3539.
23. Rüssmann H, Shams H, Poblete F, Fu Y, Galan JE, et al. (1998) Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science 281: 565-568.
24. Rüssmann H, Gerdemann U, Igwe EI, Panthel K, Heesemann J, et al. (2003) Attenuated Yersinia pseudotuberculosis carrier vaccine for simultaneous antigenspecific CD4 and CD8 T-cell induction. Infect Immun 71: 3463-3472.
25. Sory MP, Boland A, Lambermont I, Cornelis GR (1995) Identification of the YopE and YopH domains required for secretion and internalization into the cytosol of macrophages, using the cyaA gene fusion approach. Proc Natl Acad Sci U S A 92: 11998-12002.
26. Charpentier X, Oswald E (2004) Identification of the secretion and translocation domain of the enteropathogenic and enterohemorrhagic Escherichia coli effector Cif, using TEM-1 beta-lactamase as a new fluorescence-based reporter. J Bacteriol 186: 5486-5495.
27. Lauwereys M, Arbabi Ghahroudi M, Desmyter A, Kinne J, Holzer W, et al. (1998) Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. Embo J 17: 3512-3520.
28. Fraile S, Munoz A, de Lorenzo V, Fernandez LA (2004) Secretion of proteins with dimerization capacity by the haemolysin type I transport system of Escherichia coli. Mol Microbiol 53: 1109-1121.
29. Rothbauer U, Zolghadr K, Muyldermans S, Schepers A, Cardoso MC, et al. (2008) A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins. Mol Cell Proteomics 7: 282-289.
30. Zarivach R, Vuckovic M, Deng W, Finlay BB, Strynadka NC (2007) Structural analysis of a prototypical ATPase from the type III secretion system. Nat Struct Mol Biol 14: 131-137.
31. Stein M, Kenny B, Stein MA, Finlay BB (1996) Characterization of EspC, a 110- kilodalton protein secreted by enteropathogenic Escherichia coli which is homologous to members of the immunoglobulin A protease-like family of secreted proteins. J Bacteriol 178: 6546-6554.
32. Heuck AP, Tweten RK, Johnson AE (2003) Assembly and topography of the prepore complex in cholesterol-dependent cytolysins. J Biol Chem 278: 31218-31225.
33. Palmer M, Harris R, Freytag C, Kehoe M, Tranum-Jensen J, et al. (1998) Assembly mechanism of the oligomeric streptolysin O pore: the early membrane lesion is lined by a free edge of the lipid membrane and is extended gradually during oligomerization. EMBO J 17: 1598-1605.
34. Dean P, Maresca M, Schuller S, Phillips AD, Kenny B (2006) Potent diarrheagenic mechanism mediated by the cooperative action of three enteropathogenic Escherichia coli-injected effector proteins. Proc Natl Acad Sci U S A 103: 1876-1881.
35. Daniell SJ, Kocsis E, Morris E, Knutton S, Booy FP, et al. (2003) 3D structure of EspA filaments from enteropathogenic Escherichia coli. Mol Microbiol 49: 301-308.
36. Marches O, Covarelli V, Dahan S, Cougoule C, Bhatta P, et al. (2008) EspJ of enteropathogenic and enterohaemorrhagic Escherichia coli inhibits opsonophagocytosis. Cell Microbiol 10: 1104-1115.
37. Whale AD, Hernandes RT, Ooka T, Beutin L, Schuller S, et al. (2007) TccP2- mediated subversion of actin dynamics by EPEC 2 - a distinct evolutionary lineage of enteropathogenic Escherichia coli. Microbiology 153: 1743- 1755.
38. Wu Y, Lau B, Smith S, Troyan K, Barnett Foster DE (2004) Enteropathogenic Escherichia coli Infection Triggers Host Phospholipid Metabolism Perturbations. Infect Immun 72: 6764-6772.
39. Petty NK, Bulgin R, Crepin VF, Cerdeno-Tarraga AM, Schroeder GN, et al. (2010) The Citrobacter rodentium Genome Sequence Reveals Convergent Evolution with Human Pathogenic Escherichia coli. J Bacteriol 192: 525-538.
40. Donnenberg MS, Tacket CO, James SP, Losonsky G, Nataro JP, et al. (1993) Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. J Clin Invest 92: 1412-1417.
41. Posfai G, Plunkett G, 3rd, Feher T, Frisch D, Keil GM, et al. (2006) Emergent properties of reduced-genome Escherichia coli. Science 312: 1044-1046.
42. McDaniel TK, Kaper JB (1997) A cloned pathogenicity island from enteropathogenic Escherichia coli confers the attaching and effacing phenotype on E. coli K-12. Mol Microbiol 23: 399-407.
43. Brinkley C, Burland V, Keller R, Rose DJ, Boutin AT, et al. (2006) Nucleotide sequence analysis of the enteropathogenic Escherichia coli adherence factor plasmid pMAR7. Infect Immun 74: 5408-5413.
44. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, et al. (2000) Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289: 1352-1355.
45. Krüger C, Hu Y, Pan Q, Marcotte H, Hultberg A, et al. (2002) In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nat Biotechnol 20: 702-706.
46. Wells JM, Mercenier A (2008) Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Micro 6: 349-362.
47. Lewis GK (2007) Live-attenuated Salmonella as a prototype vaccine vector for passenger immunogens in humans: are we there yet? Expert Rev Vaccines 6: 431-440.
48. Stritzker J, Pilgrim S, Szalay AA, Goebel W (2008) Prodrug converting enzyme gene delivery by L. monocytogenes. BMC Cancer 8: 94.
49. Singh R, Paterson Y (2006) Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy. Expert Rev Vaccines 5: 541-552.
50. Nishikawa H, Sato E, Briones G, Chen LM, Matsuo M, et al. (2006) In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest 116: 1946-1954.
51. Cheng CM, Lu YL, Chuang KH, Hung WC, Shiea J, et al. (2008) Tumortargeting prodrug-activating bacteria for cancer therapy. Cancer Gene Ther 15: 393-401.
52. Friedlos F, Lehouritis P, Ogilvie L, Hedley D, Davies L, et al. (2008) Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy. Clin Cancer Res 14: 4259-4266.
53. Fu W, Lan H, Liang S, Gao T, Ren D (2008) Suicide gene/prodrug therapy using Salmonella-mediated delivery of Escherichia coli purine nucleoside phosphorylase gene and 6-methoxypurine 29-deoxyriboside in murine mammary carcinoma 4T1 model. Cancer Sci 99: 1172-1179.
54. Zhu X, Zhou P, Cai J, Yang G, Liang S, et al. (2010) Tumor antigen delivered by Salmonella III secretion protein fused with heat shock protein 70 induces protection and eradication against murine melanoma. Cancer Sci.
55. Grozdanov L, Raasch C, Schulze J, Sonnenborn U, Gottschalk G, et al. (2004) Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. J Bacteriol 186: 5432-5441.
56. Henker J, Muller S, Laass MW, Schreiner A, Schulze J (2008) Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Z Gastroenterol 46: 874-875.
57. Schultz M (2008) Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 14: 1012-1018.
58. Andersson P, Engberg I, Lidin-Janson G, Lincoln K, Hull R, et al. (1991) Persistence of Escherichia coli bacteriuria is not determined by bacterial adherence. Infect Immun 59: 2915-2921.
59. Sunden F, Hakansson L, Ljunggren E, Wullt B (2006) Bacterial interference-is deliberate colonization with Escherichia coli 83972 an alternative treatment for patients with recurrent urinary tract infection? Int J Antimicrob Agents 28 Suppl 1: S26-29.
60. Sunden F, Hakansson L, Ljunggren E, Wullt B (2010) Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J Urol 184: 179-185.
61. Stritzker J, Weibel S, Hill PJ, Oelschlaeger TA, Goebel W, et al. (2007) Tumorspecific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol 297: 151-162.
62. Forbes NS (2010) Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer.
63. Tanaka T, Williams RL, Rabbitts TH (2007) Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. EMBO J 26: 3250-3259.
64. McGonigal K, Tanha J, Palazov E, Li S, Gueorguieva-Owens D, et al. (2009) Isolation and functional characterization of single domain antibody modulators of Caspase-3 and apoptosis. Appl Biochem Biotechnol 157: 226-236.
65. Van den Abbeele A, De Clercq S, De Ganck A, De Corte V, Van Loo B, et al. (2010) A llama-derived gelsolin single-domain antibody blocks gelsolin-G-actin interaction. Cell Mol Life Sci 67: 1519-1535.
66. Vercruysse T, Pardon E, Vanstreels E, Steyaert J, Daelemans D (2010) An Intrabody Based on a Llama Single-domain Antibody Targeting the N-terminal OE6-Helical Multimerization Domain of HIV-1 Rev Prevents Viral Production. Journal of Biological Chemistry 285: 21768-21780.
67. Scheele JS, Rhee JM, Boss GR (1995) Determination of absolute amounts of GDP and GTP bound to Ras in mammalian cells: comparison of parental and Ras-overproducing NIH 3T3 fibroblasts. Proceedings of the National Academy of Sciences of the United States of America 92: 1097-1100.
68. Svingen PA, Loegering D, Rodriquez J, Meng XW, Mesner PW, et al. (2004) Components of the Cell Death Machine and Drug Sensitivity of the National Cancer Institute Cell Line Panel. Clinical Cancer Research 10: 6807-6820.
69. Yanish-Perron C, Viera J, Messing J (1985) Improved M13 Phage cloning vectors and hosts strains: nucleotide sequences of the M13mp18 and pU19 vectors. Gene 33: 103-119.
70. Garmendia J, Phillips AD, Carlier MF, Chong Y, Schuller S, et al. (2004) TccP is an enterohaemorrhagic Escherichia coli O157:H7 type III effector protein that couples Tir to the actin-cytoskeleton. Cell Microbiol 6: 1167-1183.
71. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, et al. (2002) Short Protocols in Molecular Biology. New York: John Wiley & Sons, Inc.
72. Schlosser-Silverman E, Elgrably-Weiss M, Rosenshine I, Kohen R, Altuvia S (2000) Characterization of Escherichia coli DNA lesions generated within J774 macrophages. J Bacteriol 182: 5225-5230.
73. Rothbauer U, Zolghadr K, Tillib S, Nowak D, Schermelleh L, et al. (2006) Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat Methods 3: 887-889.
74. Turner DL, Weintraub H (1994) Expression of achaete-scute homolog 3 in Xenopus embryos converts ectodermal cells to a neural fate. Genes Dev 8: 1434-1447.
75. Jordan M, Schallhorn A, Wurm FM (1996) Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res 24: 596-601.
76. Jurado P, Ritz D, Beckwith J, de Lorenzo V, Fernández LA (2002) Production of functional single-chain Fv antibodies in the cytoplasm of Escherichia coli. J Mol Biol 320: 1-10.
77. Fontana J, Tzeng WP, Calderita G, Fraile-Ramos A, Frey TK, et al. (2007) Novel replication complex architecture in rubella replicon-transfected cells. Cell Microbiol 9: 875-890.